BATM Advanced Communications (BATM), a diagnostics business has received licence from China Food and Drug Administration to import, market and sell its diagnostic kit for hepatitis C virus (HCV) in China.
The diagnostic kit identifies by detecting antibodies to the virus using an ELISA screen.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BATM CEO Dr Zvi Marom said: "China is the world’s largest market for hepatitis C diagnostics, and we believe that this approval will pave the way for the granting of licences for several more reagents that we have submitted for approval.
"Hepatitis C disease currently has no vaccine and it is estimated to kill approximately 350,000-500,000 every year, a number far greater than the recent tragedy spread by the Ebola virus.
"Our ambition is to ensure that the diagnosis of this killer virus, in China and elsewhere, becomes a standard and its prevalence is reduced through proper care and treatment."
The diagnostics business is focused on developing products for small to mid-size laboratories, including advanced genomic solutions that are being introduced to the market.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataShipments of first units are expected to be started in the second half of 2015, with the group targeting hospitals in the Shanghai province. Upon completion of this, the group intends to begin sales and marketing efforts to other provinces in China.
The diagnostics business offers solution to the group, which is targeting markets where many laboratories are mid-sized and dispersed in different localities.
